Background: 11C PIB PET has been shown to correlate with the presence of brain amyloid
in patients with neurodegenerative disease. The short half-life of 11C makes the clinical use�…

Background 11 C PIB PET has been shown to correlate with the presence of brain amyloid
in patients with neurodegenerative disease. The short half-life of 11 C makes the clinical use�…

922 Objectives: C11 PIB PET has been shown to correlate with the presence amyloid in
neurodegenerative disease. The short half-life of C11 PIB makes its clinical use problematic�…

Background: The relationship between amyloid load and cognitive function remains unclear.
In vivo imaging of amyloid in individuals representing a spectrum of cognitive impairment�…

Background Access to the Aβ tracer 11C-PiB is restricted by its short half-life. 18F-BAY94–
9172 is a new Aβ tracer with a longer decay half-life better suited to widespread clinical use�…

Background Clinical brain amyloid imaging would be facilitated by availability of an 18 F-
labeled compound without the need of an on-site cyclotron. In view of the knowledge built up�…

Background 11 C-PIB PET has proven useful for the detection of beta-amyloid (Aβ) in vivo in
Alzheimer's disease. However, the 20-minute half-life of C-11 restricts the use of PIB to�…

Background Depositions of amyloid-β protein in the brain is one of the neuropathological
hallmarks in Alzheimer's disease (AD). Our previous studies demonstrated that a PET�…

Background Positron emission tomography (PET) with [11C] PIB has been used to
quantitate and visualize the accumulation of amyloid beta in Alzheimer's disease (AD)�…

Background There is growing research and clinical need for in vivo quantification of amyloid
in Alzheimer's disease (AD) for diagnosis and assessment of treatment response, but to date�…